Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04814095 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc

Study acronym: PREDiCTc
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: May 1, 2025 to May 1, 2028v6
  2. Re-verified, no change to tracked fieldsv5
  3. Primary completion date: May 1, 2023 to May 1, 2025v4
  4. Start date changed from estimate of May 1, 2021 to Jun 30, 2021v3
  5. Trial status: Not Yet Recruiting to Recruiting Start date: Apr 1, 2021 to May 1, 2021 · Study sites: 0 to 1 · Primary completion date: Apr 1, 2023 to May 1, 2023 · 1 morev2 Show 4 more changesShow less
    • Start date: Apr 1, 2021 to May 1, 2021
    • Study sites: 0 to 1
    • Primary completion date: Apr 1, 2023 to May 1, 2023
    • Completion date: Apr 1, 2025 to May 1, 2025
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare cancers or cancer harbouring rare molecular aberrations. The treatment has been granted conditional or full approved by Health Canada (HC) as effective and safe. Due to the rarity of the cancer or molecular aberration the uncertainty level of the health technology assessment (HTA) by the pan Canadian Oncology Review (pCODR) was too high for consideration of funding or it was not submitted for consideration. Consequently, the goal of this study is to generate real world evidence to support HTA decision making throughout the life cycle of the product.
Trial Details
NCT Number NCT04814095
Lead Sponsor British Columbia Cancer Agency
Conditions Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov